Publications by authors named "Shu Ning"

Claim this Profile
I
IGFBP3-SphK1/S1P Signaling Axis Drives Enzalutamide Resistance in Advanced Prostate Cancer.
Amy R Leslie, Shu Ning, Masuda Sharifi, Zachary A Schaaf, James P Maine

Mol Cancer Ther· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Machine Learning-Based Prognostic Modeling of Seven Signatures Associated with Lysosomes for Predicting Prognosis and Immune Status in Clear Cell Renal Cell Carcinoma.
Jie Chen, Bo Chen, Mengli Zhu, Yin Huang, Shu Ning

Oncol Res Treat· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
TNF-α modulates cell proliferation via SOX4/TGF-β/Smad signaling in benign prostatic hyperplasia.
Jinze Li, Bo Chen, Yin Huang, Xinyang Liao, Jia You, Shu Ning

Cell Death Dis· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Steroid Sulfatase Regulates Metabolic Reprogramming in Advanced Prostate Cancer.
Masuda Sharifi, Cameron M Armstrong, Shu Ning, Amy R Leslie, Zachary A Schaaf

Cancers (Basel)· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: Novel inhibition of AKR1C3 and androgen receptor axis by PTUPB synergizes enzalutamide treatment in advanced prostate cancer.
Joy C Yang, Pengfei Xu, Shu Ning, Logan J Wasielewski, Hans Adomat

Oncogene· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synergistic effects of immunotherapy and adjunctive therapies in prostate cancer management.
Jie Chen, Na Ma, Bo Chen, Yin Huang, Jinze Li, Shu Ning

Crit Rev Oncol Hematol· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
LX1 Dual Targets AR Variants and AKR1C3 in Advanced Prostate Cancer Therapy.
Shu Ning, Cameron M Armstrong, Enming Xing, Amy R Leslie, Richard Y Gao

Cancer Res· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PINK1-Mediated Mitochondrial Activity Confers Olaparib Resistance in Prostate Cancer Cells.
Zachary A Schaaf, Shu Ning, Amy R Leslie, Masuda Sharifi, Richard Y Gao

Cancer Res Commun· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Proteostasis perturbation of N-Myc leveraging HSP70 mediated protein turnover improves treatment of neuroendocrine prostate cancer.
Pengfei Xu, Joy C Yang, Bo Chen, Shu Ning, Xiong Zhang

Nat Commun· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Plexin D1 emerges as a novel target in the development of neural lineage plasticity in treatment-resistant prostate cancer.
Bo Chen, Pengfei Xu, Joy C Yang, Christopher Nip, Leyi Wang, Shu Ning

Oncogene· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Plexin D1 emerges as a novel target in the development of neural lineage plasticity in treatment-resistant prostate cancer.
Chengfei Liu, Bo Chen, Pengfei Xu, Joy Yang, Christopher Nip, Shu Ning

Res Sq· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
IGFBP3 promotes resistance to Olaparib via modulating EGFR signaling in advanced prostate cancer.
Amy R Leslie, Shu Ning, Cameron M Armstrong, Leandro S D'Abronzo, Masuda Sharifi

iScience· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Therapeutic Resistance Models and Treatment Sequencing in Advanced Prostate Cancer.
Zachary A Schaaf, Shu Ning, Amy R Leslie, Masuda Sharifi, Xianrui Han

Cancers (Basel)· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Allosteric inhibition of HSP70 in collaboration with STUB1 augments enzalutamide efficacy in antiandrogen resistant prostate tumor and patient-derived models.
Pengfei Xu, Joy C Yang, Shu Ning, Bo Chen, Christopher Nip

Pharmacol Res· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel inhibition of AKR1C3 and androgen receptor axis by PTUPB synergizes enzalutamide treatment in advanced prostate cancer.
Joy C Yang, Pengfei Xu, Shu Ning, Logan J Wasielewski, Hans Adomat

Oncogene· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bioengineered BERA-Wnt5a siRNA Targeting Wnt5a/FZD2 Signaling Suppresses Advanced Prostate Cancer Tumor Growth and Enhances Enzalutamide Treatment.
Shu Ning, Chengfei Liu, Wei Lou, Joy C Yang, Alan P Lombard

Mol Cancer Ther· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
Wntless expression promotes lineage plasticity and is associated with neuroendocrine prostate cancer.
Leandro S D'Abronzo, Alan P Lombard, Shu Ning, Cameron M Armstong, Amy R Leslie

Am J Clin Exp Urol· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Activation of neural lineage networks and ARHGEF2 in enzalutamide-resistant and neuroendocrine prostate cancer and association with patient outcomes.
Shu Ning, Jinge Zhao, Alan P Lombard, Leandro S D'Abronzo, Amy R Leslie

Commun Med (Lond)· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Olaparib-Induced Senescence Is Bypassed through G2-M Checkpoint Override in Olaparib-Resistant Prostate Cancer.
Alan P Lombard, Cameron M Armstrong, Leandro S D'Abronzo, Shu Ning, Amy R Leslie

Mol Cancer Ther· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Activation of the Amplicon in Docetaxel- and Cabazitaxel-Resistant Prostate Cancer Cells.
Alan P Lombard, Wei Lou, Cameron M Armstrong, Leandro S D'Abronzo, Shu Ning

Mol Cancer Ther· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
ARVib suppresses growth of advanced prostate cancer via inhibition of androgen receptor signaling.
Chengfei Liu, Cameron M Armstrong, Shu Ning, Joy C Yang, Wei Lou

Oncogene· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Steroid Sulfatase Stimulates Intracrine Androgen Synthesis and is a Therapeutic Target for Advanced Prostate Cancer.
Cameron M Armstrong, Chengfei Liu, Liangren Liu, Joy C Yang, Wei Lou, Ruining Zhao, Shu Ning

Clin Cancer Res· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cross-Resistance Among Next-Generation Antiandrogen Drugs Through the AKR1C3/AR-V7 Axis in Advanced Prostate Cancer.
Jinge Zhao, Shu Ning, Wei Lou, Joy C Yang, Cameron M Armstrong

Mol Cancer Ther· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Crystal Structures, Stabilities, Electronic Properties, and Hardness of MoB2: First-Principles Calculations.
Li-Ping Ding, Peng Shao, Fang-Hui Zhang, Cheng Lu, Lei Ding, Shu Ya Ning

Inorg Chem· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cortex mapping of ipsilateral somatosensory area following anatomical hemispherectomy: a MEG study.
Ning Yao, Hui Qiao, Ning Shu, Zide Wang, Daxing Chen

Brain Dev· April 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis